# Prevention of Thrombocytopenia in Glioblastoma Patients

> **NCT02227576** · PHASE2 · TERMINATED · sponsor: **University Hospital, Lille** · enrollment: 20 (actual)

## Conditions studied

- Thrombocytopenia
- Glioblastoma

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT02227576
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-10
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227576, "Prevention of Thrombocytopenia in Glioblastoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02227576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*